Kabazitaksel Fresenius Kabi (Cabazitaxel)

Cabazitaxel belongs to the taxane class. It binds to β‑tubulin, stabilising microtubules and preventing their disassembly. This interferes with the mitotic spindle, causing cell‑cycle arrest at the G2/M phase and leading to apoptosis of rapidly dividing cancer cells.

The exact dose is determined by the prescribing oncologist based on patient weight, body surface area, prior therapies, and laboratory values. A common regimen is 25 mg/m² given as an intravenous infusion every three weeks, but clinicians may adjust the schedule according to individual tolerance and response.

Cabazitaxel is classified as contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for several weeks after the last dose. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

The primary alternative in this therapeutic area is docetaxel, another taxane. Cabazitaxel has demonstrated activity in tumors that have become resistant to docetaxel, offering a survival benefit in that setting. Both agents share similar toxicity profiles, but cabazitaxel may have a higher incidence of neutropenia while showing less cross‑resistance.

Kabazitaksel Fresenius Kabi must be stored refrigerated at 2 °C to 8 °C. The vial should be kept in its original packaging, protected from light, and should never be frozen or shaken. Prior to administration, the solution may be allowed to reach room temperature, but it must remain sterile.

The product is supplied as a sterile injectable solution for intravenous infusion. It is typically administered over 1 hour through a peripheral or central line under clinical supervision. Infusion time and pre‑medication (e.g., anti‑emetics, antihistamines) are decided by the treating physician based on patient tolerance.

The most critical adverse events include severe neutropenia and febrile neutropenia, which can lead to life‑threatening infections; hypersensitivity reactions ranging from rash to anaphylaxis; and pulmonary toxicity presenting as cough or shortness of breath. Prompt medical evaluation is required if any of these symptoms develop.

Cabazitaxel is contraindicated in patients with known hypersensitivity to the drug or its excipients, those with severe hepatic impairment, and individuals with uncontrolled active infections. Caution is also advised for patients with pre‑existing cardiac disease or significant bone‑marrow suppression.